A327610 Stock Overview
Femtobiomed Inc. engages in the development of cargo-free intracellular delivery platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Femtobiomed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,200.00 |
| 52 Week High | ₩10,870.00 |
| 52 Week Low | ₩4,600.00 |
| Beta | 0 |
| 1 Month Change | -7.66% |
| 3 Month Change | -4.98% |
| 1 Year Change | 2.89% |
| 3 Year Change | -13.99% |
| 5 Year Change | n/a |
| Change since IPO | -27.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| A327610 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.3% | 2.9% | 2.7% |
| 1Y | 2.9% | 10.0% | 5.8% |
Return vs Industry: A327610 underperformed the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A327610 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A327610 volatility | |
|---|---|
| A327610 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A327610's share price has been volatile over the past 3 months.
Volatility Over Time: A327610's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.femtobiomed.com |
Femtobiomed Inc. engages in the development of cargo-free intracellular delivery platform. The company, through its platform, CELLSHOT, is working on cell-based therapeutic pipelines. Its platform provides unprecedented approaches to cell therapeutics and cell biology research.
Femtobiomed Inc. Fundamentals Summary
| A327610 fundamental statistics | |
|---|---|
| Market cap | ₩67.73b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A327610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A327610 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A327610 perform over the long term?
See historical performance and comparison